SBOMs are becoming a design-time control for medtech cybersecurity

At a glance

What this is: This analysis argues that SBOMs have moved from static inventory to an operational requirement for medical device cybersecurity and regulatory evidence.

Why it matters: It matters because medtech teams now need traceable component visibility, faster vulnerability triage, and cross-functional ownership of software risk across engineering, compliance, and security.

By the numbers:

• About 96% of medical device software leverages open source, creating a complex blend of proprietary and open source components.

👉 Read Kusari's analysis of SBOM requirements for medtech cybersecurity and patient safety

Context

Medical device cybersecurity is no longer limited to perimeter protection or post-market patching. In practice, the security problem is software provenance, component lifecycle, and the ability to prove what is inside a device before it ships. That creates a governance challenge for medtech teams, because software bills of materials only matter when they are tied to ownership, vulnerability intelligence, and remediation workflows.

The article also reflects a wider identity-and-access lesson: transparency is a control only when it supports accountable action. For organisations that manage sensitive software, workloads, or device ecosystems, the same lifecycle discipline that applies to IAM, PAM, and NHI governance applies here in a different form, especially where supply chain risk and regulated environments intersect. See the Ultimate Guide to NHIs , Key Challenges and Risks for the broader lifecycle-control lens.

Key questions

Q: How should medical device teams make SBOMs operational instead of treating them as paperwork?

A: SBOMs become operational when they are generated automatically, machine-readable, and continuously matched to vulnerability and exploitability data. Teams should connect component inventory to ownership, support status, and remediation workflows so the result drives release decisions, regulatory evidence, and incident response rather than sitting in a document repository.

Q: Why do SBOMs matter so much for regulated medical devices?

A: They provide the evidence base for understanding what software is inside a device, which components are unsupported, and where known vulnerabilities may affect patient safety or product availability. In regulated environments, that traceability is essential because it links technical risk to quality, compliance, and customer communication obligations.

Q: What breaks when SBOMs are not kept current?

A: An outdated SBOM weakens vulnerability triage, supplier review, and incident response because it no longer reflects what is actually deployed. When the software inventory drifts, teams waste time chasing false assumptions or miss affected applications entirely. That turns a useful control into a reporting artifact.

Q: Who is accountable when a medical device cyber issue affects patient safety?

A: Accountability sits with the manufacturer for ensuring cybersecurity does not compromise clinical performance, but healthcare operators also need ownership for deployment, monitoring, and maintenance. The practical question is not who caused the weakness alone, but who controls the patch path, the risk decision, and the response when patient harm becomes plausible.

Technical breakdown

Why SBOMs only work when tied to exposure data

An SBOM is a machine-readable inventory of software components, versions, and origins. By itself, it is a list, not a risk decision. The practical value appears when the SBOM is correlated with vulnerability feeds such as CVEs and, where available, VEX data that distinguishes theoretical exposure from confirmed exposure. That correlation turns component visibility into triage, allowing teams to separate unsupported, exploitable, and safely mitigated dependencies. In regulated device environments, this is the difference between proving inventory and proving control.

Practical implication: build a workflow that combines SBOM intake, CVE matching, and VEX review before release decisions are made.

Why software anomalies matter alongside component inventories

FDA guidance increasingly treats known software anomalies as part of the security evidence chain. An anomaly is not just a bug report. It is a documented issue that must be assessed for safety impact, exploitability, and mitigation status. That matters because medical devices have dual obligations: they must remain secure and they must continue to function safely for patients. A component can be present, supported, and still introduce unacceptable risk if the anomaly affects critical function or is actively exploitable.

Practical implication: add anomaly review to security sign-off so engineering and regulatory teams assess safety impact together.

How machine-readable SBOMs support ecosystem response

Machine-readable SBOMs matter because hospitals, regulators, and manufacturers need to query device populations quickly when a vulnerability emerges. A static PDF cannot support rapid comparison across product lines, versions, and deployment contexts. Standardised records enable automated matching against threat intelligence and faster communication with downstream buyers. In a medtech environment, that shortens the gap between vulnerability disclosure and patient-risk assessment, which is where operational resilience is won or lost.

Practical implication: standardise SBOM generation in the build pipeline so downstream customers can consume and act on it without manual rework.

Threat narrative

Attacker objective: The objective is to disrupt medical operations or exploit software weakness in a way that creates clinical, regulatory, or business damage.

1. Entry occurs through vulnerable or unsupported software components embedded in a medical device supply chain.
2. Escalation happens when an untracked dependency or known anomaly can be abused to affect device behaviour, update trust, or operational availability.
3. Impact is delayed treatment, disrupted manufacturing, or compromised patient safety when the device or its supporting ecosystem cannot be trusted or recovered quickly.

NHI Mgmt Group analysis

SBOMs are becoming a lifecycle governance control, not a compliance artifact. The article shows that component visibility only becomes meaningful when it is tied to ownership, exposure, and remediation. That is the same governance pattern identity teams know from credential and privilege lifecycle management, where inventory without action is not control. For medtech, the practitioner conclusion is simple: treat SBOMs as operational evidence, not filing material.

Software provenance has become part of patient safety governance. When 96% of device software depends on open source, the real issue is not whether components exist but whether their provenance, support status, and exploitability are known. That shifts accountability from engineering alone to shared quality, security, and regulatory ownership. The practitioner conclusion is that software risk in medical devices now needs executive-level traceability.

Design-time security is replacing reactive patching as the default model. The article is clear that post-market fixes are too slow for clinical environments where vulnerabilities can affect therapy, availability, and trust. That aligns with broader supply-chain security thinking in NIST-CSF and NIST SP 800-53, where identification, monitoring, and response must be built into the system life cycle. The practitioner conclusion is to move security review upstream before release gates close.

Machine-readable disclosure is the only version of transparency that scales. A static inventory does not help when regulators, hospitals, and manufacturers need to correlate component data against live vulnerability intelligence. This is the same lesson identity programmes learned with lifecycle automation: data that cannot drive decisions does not reduce risk. The practitioner conclusion is to standardise disclosure formats before the next incident forces manual work.

SBOM governance will increasingly intersect with regulated access and vendor accountability. Where medical devices are connected to enterprise systems, the control problem extends beyond software content to who can modify, distribute, or attest to that content. That creates a genuine intersection with IAM-style accountability, even if the core topic is not identity itself. The practitioner conclusion is to map SBOM ownership, approval, and release authority to named roles and auditable workflows.

What this signals

Medical device cybersecurity teams should expect SBOM governance to converge with supplier assurance, vulnerability management, and regulated change control. The programme risk is not only whether a component is listed, but whether the organisation can prove who owns its risk, how fast it can assess exposure, and how it communicates across the clinical supply chain.

Transparency debt: when component inventories exist but cannot be operationalised, organisations carry a hidden control debt that surfaces during disclosure events and regulatory reviews. That is a useful lens for any programme trying to turn static records into decision-ready assurance.

Teams should align SBOM operations with standards-based evidence handling, including NIST SP 800-53 controls for configuration management and system integrity, and use the NIST SP 800-53 Rev 5 Security and Privacy Controls as a reference point for governance design.

For practitioners

• Move SBOM review into premarket control gates Require SBOM completeness, component support status, and remediation evidence before design freeze or submission, not after release. That prevents late discovery of unsupported or exploitable dependencies.
• Correlate SBOMs with CVE and VEX data continuously Automate matching so teams can distinguish theoretical exposure from confirmed exposure and prioritise devices with active exploitability or patient safety impact.
• Assign named owners for component risk decisions Make engineering, quality, regulatory, and security jointly accountable for each high-risk dependency so remediation timelines and mitigation choices are traceable.
• Standardise machine-readable disclosure for downstream recipients Provide hospitals and buyers with SBOM outputs they can ingest directly, so product support teams can answer exposure questions quickly during incident response.
• Track software anomalies as part of safety assurance Record known anomalies with exploitability and safety impact assessments so regulators and internal approvers see risk in operational context, not as isolated defects.

Key takeaways

• SBOMs are now a design-time control for medical devices, not a late-stage compliance deliverable.
• Component visibility only reduces risk when it is linked to vulnerability intelligence, anomaly review, and named accountability.
• Medtech teams that cannot operationalise software provenance will struggle to satisfy both patient-safety expectations and regulatory scrutiny.

Key terms

• Software Bill of Materials: A software bill of materials is an inventory of the components and dependencies used in an application. It helps teams identify what they shipped, but it becomes most useful when paired with source verification, signature checks, and policy enforcement for third-party code.
• Vex: VEX, or Vulnerability Exploitability eXchange, is a way to state whether a known vulnerability is exploitable in a specific product, build, or deployment. It helps security teams avoid treating every matching CVE as equally urgent and improves prioritisation in software supply chains.
• Software Anomaly: A software anomaly is a documented defect, irregularity, or condition that may affect how a device behaves, especially under attack or failure conditions. In medtech, anomalies matter because they must be assessed not only for technical severity, but also for safety impact, exploitability, and mitigation status.
• Software provenance: Software provenance is the evidence that shows where an artifact came from, who created it, and whether it was altered before use. For security teams, it means signed releases, controlled build paths, and verification steps that reduce the chance of trusted software carrying hidden malicious changes.

What's in the full article

Kusari's full blog post covers the implementation detail this post intentionally leaves for the source:

• The FDA submission expectations for machine-readable SBOM content, including component origin, support status, and end-of-life data
• The practical workflow for correlating SBOMs with vulnerability databases and determining whether a device is actually exposed
• The cross-functional operating model that links engineering, quality, regulatory, and legal teams to software-risk decisions
• The process for sharing SBOM intelligence with hospitals and healthcare delivery organisations during vulnerability response

👉 Kusari's full post expands on FDA expectations, SBOM operationalisation, and the risk-management workflow for regulated device teams.

Deepen your knowledge

The NHI Foundation Level course, the industry's only accredited NHI security programme, covers NHI governance, machine identity security, and secrets management with a practitioner focus. It is suitable for security and risk professionals who need to connect identity controls to broader operational resilience.